Search
berotralstat (Orladeyo)
Indications:
- prevention of hereditary angioedema attacks [2]
Dosage:
- 150 mg PO QD, 110 mg PO QD for persistent GI distress [2]
110 & 150 mg oral capsule
Dosage adjustment in renal failure:
- if creatinine clearance > 15 mL/min, no dosage adjustment needed
- not recommended if creatinine clearance < 15 mL/min,
Adverse effects:
- QT prolongation (do not exceed 150 mg/day) [2]
Mechanism of action:
- kallikrein inhibitor [2]
General
kallistatin; kallikrein inhibitor; peptidase inhibitor 4; PI-4; Serpin A4 (SERPINA4, KST, PI4)
metabolic agent (metabolic modifier)
References
- RxNorm
- Medscape: berotralstat (Rx)
https://reference.medscape.com/drug/orladeyo-berotralstat-4000073
- Ohsawa I, Honda D, Suzuki Y, et al
Oral berotralstat for the prophylaxis of hereditary angioedema attacks
in patients in Japan: A phase 3 randomized trial.
Allergy. 2020 Nov 28
PMID: 33247955